AdvanCell
Sydney
About AdvanCell
AdvanCell is a clinical-stage radiopharmaceutical company that develops novel cancer therapeutics. It develops alpha-emitting isotopes attached to molecules that deliver cytotoxic radiation directly to tumors at the molecular level to allow healthcare providers to provide safe and effective treatment for multiple forms of cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $137.9M
- Funding stage: Late Stage Venture
- Last round: Grant (Apr 2025)
- Website: advancell.com.au
Industries & Categories
Biotechnology, Clinical Trials, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/advancell-95920 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.